S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
What to Expect from the Markets in a Recession
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
What to Expect from the Markets in a Recession
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
What to Expect from the Markets in a Recession
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
What to Expect from the Markets in a Recession
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:KURA

Kura Oncology - KURA Stock Forecast, Price & News

$15.49
+0.41 (+2.72%)
(As of 08/5/2022 08:48 PM ET)
Add
Compare
Today's Range
$14.56
$15.78
50-Day Range
$13.07
$19.45
52-Week Range
$10.41
$21.19
Volume
792,800 shs
Average Volume
791,850 shs
Market Capitalization
$1.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50

Kura Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
142.1% Upside
$37.50 Price Target
Short Interest
Bearish
8.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.65mentions of Kura Oncology in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.18) to ($2.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

584th out of 1,283 stocks

Pharmaceutical Preparations Industry

273rd out of 615 stocks

KURA stock logo

About Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology Trading Up 2.7 %

NASDAQ:KURA opened at $15.49 on Monday. The stock has a 50-day simple moving average of $15.96 and a 200 day simple moving average of $15.01. The company has a market capitalization of $1.03 billion, a PE ratio of -7.75 and a beta of 0.92. Kura Oncology has a 12 month low of $10.41 and a 12 month high of $21.19.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Cantor Fitzgerald assumed coverage on shares of Kura Oncology in a research report on Tuesday, July 12th. They set an "overweight" rating and a $30.00 target price on the stock. StockNews.com downgraded shares of Kura Oncology from a "hold" rating to a "sell" rating in a research note on Wednesday, May 18th. Credit Suisse Group upped their price target on Kura Oncology from $27.00 to $29.00 and gave the stock an "outperform" rating in a report on Wednesday, July 13th. Finally, Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Kura Oncology in a research note on Thursday. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $37.50.

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Stock News Headlines

Earnings Preview: Kura Oncology
Kura Oncology (NASDAQ:KURA) PT Raised to $29.00
Kura Oncology Stock Scores Rising Relative Strength
Kura Oncology Q1 2022 Earnings Preview
Kura Oncology: Q4 Earnings Insights
See More Headlines
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Company Calendar

Last Earnings
11/04/2021
Today
8/07/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.50
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+142.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-130,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.72 per share

Miscellaneous

Free Float
63,281,000
Market Cap
$1.03 billion
Optionable
Optionable
Beta
0.92

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 53)
    Ph.D., Chairman, CEO, Pres & Principal Financial Officer
    Comp: $984.61k
  • Ms. Kathleen Ford (Age 75)
    Chief Operating Officer
    Comp: $689.32k
  • Dr. Marc Grasso M.D. (Age 48)
    Advisor
    Comp: $651.68k
  • Ms. Kirsten Flowers (Age 47)
    Chief Commercial Officer
    Comp: $642.98k
  • Dr. Stephen Dale M.D. (Age 50)
    Chief Medical Officer
    Comp: $811.58k
  • Mr. Thomas Doyle (Age 51)
    Principal Accounting Officer & Sr. VP of Fin. and Accounting
  • Mr. Pete De Spain
    Sr. VP of Investor Relations & Corp. Communications
  • Ms. Teresa Brophy Bair Esq. (Age 51)
    J.D., Chief Legal Officer & Corp. Sec.
  • Mr. James E. Basta J.D. (Age 56)
    Esq., Chief Compliance Officer & Corp. Sec.
  • Dr. Roger Bakale Ph.D.
    VP and Head of CMC, Clinical & Commercial Manufacturing













KURA Stock - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology
or view top-rated stocks.

What is Kura Oncology's stock price forecast for 2022?

7 Wall Street analysts have issued 1-year price targets for Kura Oncology's shares. Their KURA stock forecasts range from $26.00 to $80.00. On average, they anticipate Kura Oncology's stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 142.1% from the stock's current price.
View analysts' price targets for Kura Oncology
or view top-rated stocks among Wall Street analysts.

How has Kura Oncology's stock performed in 2022?

Kura Oncology's stock was trading at $14.00 at the beginning of the year. Since then, KURA stock has increased by 10.6% and is now trading at $15.49.
View the best growth stocks for 2022 here
.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our earnings forecast for Kura Oncology
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) posted its earnings results on Thursday, November, 4th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.04. During the same quarter in the prior year, the company earned ($0.42) earnings per share.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.74%), Victory Capital Management Inc. (1.15%), Integral Health Asset Management LLC (0.69%), Russell Investments Group Ltd. (0.18%), Aaron Wealth Advisors LLC (0.09%) and SG Americas Securities LLC (0.08%). Company insiders that own Kura Oncology stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology
.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $15.49.

How much money does Kura Oncology make?

Kura Oncology (NASDAQ:KURA) has a market capitalization of $1.04 billion. The company earns $-130,470,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 121 workers across the globe.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for Kura Oncology is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com.

This page (NASDAQ:KURA) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.